Archive for November, 2010

Patent Expirations Will Stabilize the Pharmaceutical Industry

“Patent Expirations Will Stabilize the Pharmaceutical Industry.” I must believe it, because I’m quoted in the St. Louis Observer as having said it! The reporter did a good job of capturing what I meant, quoting me as saying “the industry will be more diverse, with a more stable, though smaller, revenue base spread among many […]


Journal of Commercial Biotechnology — November 2010 issue now available

The November 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Volume 16, Issue 4 Editorial For success in biotechnology, look beyond biotechnology PDF Yali Friedman Commentary Federal bureaucrats slip on oil spill PDF Henry I Miller Articles R&D spending and […]


Drug Patent Expirations in November 2010

Drug Patent Expirations in November 2010 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration SAMSCA Otsuka America Pharm tolvaptan 5,258,510 Nov 2, 2010 TRUVADA Gilead emtricitabine; tenofovir disoproxil fumarate 5,210,085*PED Nov 11, 2010 COZAAR Merck losartan potassium 5,210,079*PED Nov 11, 2010 EMTRIVA Gilead emtricitabine 5,210,085*PED Nov 11, 2010 […]


Globalization in the pharmaceutical industry: Where are drugs invented?

I’ve just had a paper published in Nature Reviews Drug Discovery, using data from DrugPatentWatch to profile the locations of drug invention for the past decade. The location of drug development is important for two reasons. Firstly, it is important to track the global spread of innovation. Much late stage drug development (e.g. clinical trials) and […]